Friday, 18 Jan 2019

News

TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk

Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM. Based on a meta-analysis, DM cancer risk is five times higher than in the general population and twice that compared with PM cancer risk. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

Rising Physician Exclusion from Medicare and Medicaid

JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance. 

Overall the authors found that the number of physicians excluded from Medicare, Medicaid, and other state public insurance programs increased on average by 20% per year between 2007 and 2017.

Cryotherapy Never FDA Approved

Another injury related to whole body cryotherapy (WBC) has been reported by practitioners in Philadelphia, serving as yet another warning of WBC's potential to cause serious adverse effects.

RheumNow Podcast – Vasculitis and Strange Bedfellows (12.14.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com. 

CDC Top 15 Most Common Opioid Overdose Drugs

The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

No End in Sight for the Shingrix Vaccine Shortage

There is a national shortage of a new shingles vaccine, Shingrix, which is a problem for those who want to start the vaccine and those seeking to receive their second and final injection. 

Since its FDA approval nearly a year ago, sales of the new vaccine have outperformed projections and are expected to approach $1 billion in revenue for 2018. 

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis

Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0). Similarly, there are no studies comparing the most relevant comorbidities between SSc and RA.

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma.